Commerce Secretary Gina Raimondo was asked to impose anti-dumping and countervailing duties (AD/CVD) on Southeast Asian solar companies in a letter from the United Steelworkers Union (USW) on Aug. 27.
The de minimis problem is getting worse. Consider this article a “Summer 2024” update of how the de minimis catastrophe continues to escalate.
Drug shortages are becoming commonplace in the U.S. Data from a new pharmaceutical industry tracking firm, Qyobo, shows hundreds of drugs are still in short supply – some well over a year — and our dependence on imports grows, including from labs on the receiving end of lackluster FDA inspections.
China is flooding the global market with solar panels. It’s part of an aggressive strategy by Beijing to dominate the world’s solar industry.
The United States is facing an unprecedented drug shortage, with a record 323 active drug shortages at the start of 2024 — the highest number since 2001.
The foreign labs in China and India that make the branded drugs for CVS pharmacies nationwide are coming under increased scrutiny for unsafe manufacturing practices.
When drugs are pulled from pharmacy shelves, it’s somewhat of a well-kept secret that it is the pharmaceutical company that voluntarily warns buyers of the potential harm from the defect.
Generic drug exporter Zydus Lifesciences received poor marks again in April following a Food and Drug Administration inspection of its lab in Vadodara, a city in Gujarat state on India’s western coast.
The Veterans Health Administration (VHA) banned the use of plastic syringes made in China on April 23 due to safety concerns, ahead of a warning letter dated April 24 to Ohio-based importer Cardinal Health by the Food and Drug Administration.
CPA strongly supported a previous AD/CVD case filed by Auxin Solar where the Commerce Department determined that Chinese companies operating in Malaysia, Thailand, Vietnam, and Cambodia are illegally circumventing.
